Please assess the completion status of the following clinical trial:

Trial Title: Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or older, of either gender~* Patients must be tested positive for SARS-CoV-2 by RT-PCR within 72 hours prior to enrolment~* Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.~* Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening~* Patients must be under the care of a Physician for diagnosis of COVID-19~* Patients who have signed informed consent~Exclusion Criteria:~* Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin~* Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis~* Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure~* Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.~* Patients with gallstone obstruction~* Hypothyroid suffering patients~* Patients with moderate or severe thrombocytopenia (platelet count \<100 ×10⁹/L);~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Complementary therapy group (Type: EXPERIMENTAL): This arm will receive a daily supplementation of 168 mg curcumin, 260 mg quercetin and 9 mcg/360 IU of vitamin D3 (cholecalciferol) as add-on to the standard of care for 14-days
- Control group (Type: ACTIVE_COMPARATOR): This arm will receive standard care alone

Based on this trial design, predict the completion outcome and termination type (if applicable).